Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5558-5566

  Sabbota, Aaron L ^a   Kim, Hyeong Reh Choi ^a,b   Zhe, Xiaoning ^a   Fridman, Rafael ^a,b   Bonfil, R Daniel ^a,b   Cher, Michael L ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MIK G2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BONE METASTASIS; CANCER CELL; CELL MIGRATION; CELL MOTILITY; CELL STRAIN LNCAP; CHEMOTAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; HUMANS; MALE; MATRIX METALLOPROTEINASE 14; MICE; PROSTATIC NEOPLASMS; RANK LIGAND; SRC-FAMILY KINASES; TRANSFECTION;

EID: 77954355093     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4416     Document Type: Article

References (48)

1. Yamada KM. Cell biology: tumour jailbreak. Nature 2003;424:889-90.
2. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev 2005;15:87-96.
3. Sabeh F, Ota I, Holmbeck K, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004;167:769-81.
4. Zaman MH, Trapani LM, Sieminski AL, et al. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci U S A 2006;103: 10889-94.
5. Itoh Y, Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1-8.
6. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81-92.
7. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272:2446-51.
8. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003; 114:33-45.
9. Upadhyay J, Shekarriz B, Nemeth JA, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999;5:4105-10.
10. Bonfil RD, Dong Z, Trindade Filho JC, et al. Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 2007;170:2100-11.
11. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
12. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613-8. (Pubitemid 29220502)
13. Schlondorff J, Lum L, Blobel CP. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor α convertase. J Biol Chem 2001;276:14665-74. (Pubitemid 37373339)
14. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7:485-96. (Pubitemid 40719131)
15. 2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem 2005;280:41700-6.
16. Hikita A, Yana I, Wakeyama H, et al. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand. J Biol Chem 2006;281:36846-55.
17. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289-98.
18. Perez-Martinez FC, Alonso V, Sarasa JL, et al. Receptor activator of nuclear factor-κB ligand (RANKL) as a novel prognostic marker in prostate carcinoma. Histol Histopathol 2008;23:709-15.
19. Huang L, Cheng YY, Chow LT, Zheng MH, Kumta SM. Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Pathol 2002;55:877-8.
20. Odero-Marah VA, Wang R, Chu G, et al. Receptor activator of NF-κB ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 2008;18:858-70.
21. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001;57:611-6.
22. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
23. Inoue H, Nishimura K, Oka D, et al. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett 2005; 223:121-8. (Pubitemid 40693716)
24. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
25. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
26. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-61.
27. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-6.
28. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008;68:92-104.
29. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Redini F. DU145 human prostate cancer cells express functional receptor activator of NFκB: new insights in the prostate cancer bone metastasis process. Bone 2007;40:981-90.
30. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
31. Ikejiri M, Bernardo MM, Bonfil RD, et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 2005;280: 33992-4002.
32. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 1998;273:28355-9.
33. Wong BR, Besser D, Kim N, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999;4:1041-9.
34. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.
35. Dalgarno D, Thilo S, Narula S, et al. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Chem Biol Drug Des 2005;67:46-57.
36. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
37. Bonfil RD, Fridman R, Mobashery S, Cher ML. Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis? Curr Oncol 2008;15:188-92.
38. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517-26.
39. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693-702.
40. Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 1992;90:1622-7.
41. Thiolloy S, Halpern J, Holt GE, et al. Osteoclast-derived matrix metalloproteinase- 7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res 2009;69:6747-55.
42. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-75.
43. Goldenberg-Furmanov M, Stein I, Pikarsky E, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004;64:1058-66.
44. Penno H, Nilsson O, Brandstrom H, Winqvist O, Ljunggren O. Expression of RANK-ligand in prostate cancer cell lines. Scand J Clin Lab Invest 2009;69:151-5.
45. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009;182: 509-15; discussion 15-6.
46. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421-8.
47. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 2009;124:1-6.
48. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177-84.